PharmEasy

Forbes India reported that it has 12 million registered users. [2] source: Forbes India It offers at-home vaccinations, as do Tata 1mg and Apollo Homecare. [3] source: ET Small Business It acquired a 66.1% stake in Thyrocare for Rs 4,546 crore ($612 million) in June 2021. [2] source: Forbes India

API Holdings narrowed its EBITDA loss excluding Thyrocare to Rs 168 crore in FY26 from Rs 396 crore in FY25, Moneycontrol reported in October 2026. [4] source: Moneycontrol The company repaid Rs 1,050 crore of term debt and has a profitability target excluding Thyrocare of September 2027. [4] source: Moneycontrol It will decide on an IPO only after reaching that target. [4] source: Moneycontrol In May 2021, API Holdings had targeted a $1 billion-$1.2 billion IPO and appointed Morgan Stanley and Kotak as advisers. [1] source: Moneycontrol Forbes India reported a proposed Rs 2,400 crore rights issue implying a valuation of about $600 million, a 90% decline from the $5.5 billion peak in October 2021. [2] source: Forbes India PharmEasy has raised $1.2 billion across 16 funding rounds since 2014. [2] source: Forbes India

Moneycontrol's report on API Holdings also names Apollo 24/7, Netmeds and Tata 1mg. [4] source: Moneycontrol Netmeds reported FY26 revenue from operations of Rs 44.7 crore. [5] source: Indian Retailer